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Zehra Bug˘ra, MD,* Ebru Yormaz, MD,† Cüneyt Türkmen, MD,† Is¸ık Adalet, MD,†
Yilmaz Nis¸anci, MD,* Sabahattin Umman, MD*
Capa-Istanbul, Turkey
Objectives The purpose of this study was to investigate the reflections of the improvement in microvascular perfusion pro-
vided by adjuvant intracoronary streptokinase (ICSK) on late-phase infarct size and left ventricular volumes and
functions.
Background It has been shown that ICSK given immediately after primary percutaneous coronary intervention (PCI) improves
myocardial perfusion in the early days of ST-segment elevation acute myocardial infarction.
Methods Ninety-five patients undergoing primary PCI were randomized to ICSK 250 kU (n  51) or no additional therapy
(n  44). Two days later, coronary hemodynamic indexes were measured to evaluate tissue-level perfusion. Af-
ter 6 months, angiography, echocardiography, and technetium-99m single-photon emission computed tomogra-
phy (SPECT) were performed.
Results At 2 days, all indexes of microvascular function were significantly better in the ICSK group than in the control
group, including coronary flow reserve (2.5 vs. 1.7, p  0.001) and index of microvascular resistance (20.2 vs.
34.2, p  0.001). At 6 months, infarct size (22.7% vs. 32.9%; p  0.003) and left ventricular end-systolic (41.1
ml vs. 60.9 ml; p  0.009) and end-diastolic volumes (95.5 ml vs. 118.3 ml; p  0.006) were significantly
smaller, and the ejection fraction was significantly higher (57.2% vs. 51.8%; p  0.018) in the ICSK group com-
pared with the control group.
Conclusions In this study, it has been demonstrated that low-dose ICSK given immediately after primary PCI significantly limits
long-term infarct size and preserves left ventricular volumes and functions. (Effect of Complementary Intracoronary
Streptokinase Administration Immediately After Primary Percutaneous Coronary Intervention on Microvascular Perfu-
sion and Late Term Infarct Size in Patients With Acute Myocardial Infarction; NCT00302419) (J Am Coll Cardiol
2009;54:1065–71) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.04.083u
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lechanical revascularization of the infarct-related artery
IRA) is the most effective treatment modality in ST-
egment elevation myocardial infarction (STEMI). How-
ver, ongoing myocardial damage despite the successful
limination of epicardial occlusion limits its efficacy. If the
issue damage and stasis that develop in infarcted myocar-
ial segments are considered together, de novo fibrin for-
ation at the microvascular level will be found to be
rom the Departments of *Cardiology and †Nuclear Medicine, Istanbul University,
stanbul Faculty of Medicine, Capa-Istanbul, Turkey. Supported by grants from
stanbul University (BYP-637/03032005) and the Turkish Academy of Sciences.(
Manuscript received January 20, 2009; revised manuscript received April 20, 2009,
ccepted April 20, 2009.navoidable. There is a bulk of evidence pointing out that
utochthonous microvascular fibrin, vessel wall components,
irculating blood cells, and fibrinogen supplied by the
eperfusion together participate in the increase of microvas-
ular resistance (1,2). Based on this hypothesis, in a recent
tudy by our group, it has been shown that low-dose
ntracoronary fibrin/fibrinogenolytic agent (streptokinase)
dministration immediately after primary percutaneous cor-
nary intervention (PCI) significantly improves myocardial
erfusion, as was evidenced by several perfusion parameters
n the second day (3). Nevertheless, the sample size of the
tudy was not enough to assess the efficacy of the therapy on
ong-term parameters such as infarct size, left ventricular
LV) volumes, and LV function. In the present study, the
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ify the effect of adjunctive intra-
coronary streptokinase (ICSK)
administration in the setting of
primary PCI on long-term in-
farct size and LV function.
Methods
Patients. Patients within the first
12 h of STEMI undergoing pri-
mary PCI were enrolled. Major
exclusion criteria were: history
of prior myocardial infarction,
Thrombolysis In Myocardial In-
farction (TIMI) flow grade 2 or 3
at IRA, culprit lesion in a saphe-
nous vein graft, and left bundle
branch block. Written informed
consent was obtained from all pa-
tients. The study was conducted in
accordance with the Declaration of
Helsinki, and the study protocol
as approved by our hospital ethics committee.
tudy protocol. Immediately after diagnostic angiography,
ligible patients were assigned to either the ICSK or the
ontrol group based on a computer-generated random se-
uence. In both groups, IRA was stented after balloon dilation.
ll patients received 300 mg of aspirin, a loading dose of 600
g of clopidogrel, intracoronary unfractionated heparin at a
ose of 100 U/kg, and tirofiban as a bolus of 0.1 g/kg in 3
in, followed by a continuous infusion of 0.15 g/kg/min for
2 h. Invasive procedures were done with a femoral approach.
In the ICSK group, immediately after recanalizing the IRA,
50 kU of streptokinase diluted with 20 ml of saline was
nfused through the guiding catheter within 3 min. The
ontrol group received no additional treatment. Final angio-
raphic recordings were performed to assess the corrected
hrombolysis In Myocardial Infarction frame count (cTFC)
nd myocardial blush grade (MBG). Electrocardiograms were
ecorded immediately and 90 min after the procedure to assess
T-segment resolution.
icrovascular perfusion assessments. INVASIVE PARAM-
TERS. All trial subjects were recatheterized for evaluation of
icrovascular function on the second day after PCI. A
ressure-temperature sensor-tipped guide wire (Pressure wire
ensor 5, Radi Medical Systems, Uppsala, Sweden) was used
or coronary hemodynamic assessment. Papaverine was given
s an intracoronary bolus to induce maximal hyperemia. The
hermodilution-derived coronary flow reserve and the index of
icrovascular resistance were calculated as described previously
3). Coronary angiography was also performed to assess cTFC
nd MBG.
ONINVASIVE PARAMETER. Diastolic deceleration time was
easured from the coronary flow velocity spectrum in patients
Abbreviations
and Acronyms
cTFC  corrected
Thrombolysis In Myocardial
Infarction frame count
ICSK  intracoronary
streptokinase
IRA  infarct-related artery
LV  left ventricular
MBG  myocardial blush
grade
PCI  percutaneous
coronary intervention
STEMI  ST-segment
elevation myocardial
infarction
SPECT  single-photon
emission computed
tomography
TIMI  Thrombolysis In
Myocardial Infarctionhose IRA was the left anterior descending coronary artery by pransthoracic echocardiography on the second day as previously
eported (3).
ong-term follow-up. Echocardiography, angiography,
nd technetium-99m sestamibi single-photon emission
omputed tomography (SPECT) were performed 6
onths after primary PCI. LV end-diastolic and -systolic
olumes were measured and their percent changes relative
o second day values were calculated. cTFC and MBG were
eassessed from the follow-up angiogram. Technetium-99m
estamibi SPECT was used to measure infarct size, which
as expressed as a percentage of total myocardium (4) by a
uclear medicine specialist blinded to the study groups. All
oronary hemodynamic, angiographic, echocardiographic,
lectrocardiographic, and scintigraphic data were stored and
nalyzed off-line by investigators blind to the study groups.
tudy end points. The primary end point of this study
as the long-term LV infarct size. Secondary end points
ncluded LV volumes and function, and major adverse
ardiac events such as reinfarction, revascularization, and
eath.
tatistical analysis. Sample size was calculated using
raphPad Instat software (La Jolla, California). Calcu-
ations were done to estimate the necessary sample size to
etect a 30% difference between the ICSK and control
roups for infarct size (alpha: 0.05, beta: 0.20, power:
.80). Estimated mean value and standard deviations for
nfarct size were obtained from the previous study (3).
ecessary sample size was calculated as 39 patients for
ach group. Then, allocation was continued based on the
andom sequence generated for the pilot study. In this
anner, 54 more eligible patients were randomized
onsecutively in addition to 41 patients of the pilot study
n adherence with the same protocol. Final total patient
umbers in the ICSK and control groups attained were
1 and 44, respectively.
All statistical tests were performed with the Statistical
ackage for the Social Sciences program (SPSS Inc.,
hicago, Illinois). Group proportions were compared by
he chi-square or Fisher exact tests. Group means were
ompared by the Student t test for independent groups.
ategorical variables were compared by the chi-square
est. All analyses performed were repeated for the ante-
ior infarction subgroup. Group means were adjusted for
ge, pain-to-balloon time, hypertension, diabetes, pre-
nfarction angina, no-reflow, side branch embolization,
nd angiographically-measured area at risk and compared
y analysis of covariance (ANCOVA). All of the vari-
bles were distributed normally according to the
olmogorov-Smirnov test except left ventricular end-
ystolic volumes at 2 days and at 6 months. For these 2
ariables, ANCOVA was performed using their logarith-
ic values. The difference between groups with regard to
BG was first analyzed by the chi-square test, and then
logistic regression model including the above-mentioned
ovariates was built. Statistical significance was assigned to
values 0.05.
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tudy patients and angiographic outcomes. Between Oc-
ober 2004 and August 2007, 95 patients were enrolled in
he trial and allocated to either the ICSK (n  51) or
ontrol group (n  44) (Fig. 1). There was no significant
ifference between the 2 groups with respect to baseline
emographic, clinical, and angiographic characteristics, ex-
ept the mean age was lower and the pain-to-balloon time
as longer in the ICSK group (Table 1).
The IRA was successfully opened in all cases. No major
leeding occurred. Five access site complications were en-
ountered (2 minimal bleeding in each group and 1 pseu-
oaneurysm in the ICSK group). All were managed with
anual compression.
ssessment of microcirculation. Microvascular perfusion
as significantly better in the ICSK group than in the
Figure 1 Consort Diagram
Flowchart of patients. CABG  coronary artery bypass graft surgery; ICSK  intracoronontrol group, as assessed in all perfusion parameters at the
econd day as shown in Table 2. Immediately after primary
CI, there was no significant difference between the 2
roups with regard to cTFC and MBG. However, at 48 h,
he cTFC was lower and MBGs 2/3 were more frequent (86%
s. 36%; p  0.001 adjusted) in the ICSK group (Table 2).
There was no difference between the 2 groups with
espect to percent resolution of ST-segment deviation 90
in after primary PCI (Table 2).
ong-term results. Forty-five patients in the ICSK group and
5 in the control group underwent SPECT imaging at 6.2 1.7
onths. Infarct size was significantly smaller in the ICSK group
han in the control group (22.7% vs. 32.9%, p 0.003, adjusted)
Table 3, Fig. 2).
Angiographic and echocardiographic follow-ups were ob-
ained in 48 patients in the ICSK and 37 in the control group.
eptokinase; SPECT  single-photon emission computed tomography.ary str
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Intracoronary Streptokinase and Infarct Size September 15, 2009:1065–71hereas echocardiographic LV ejection fraction was not
ignificantly different between the groups at the second day, it
as higher in the ICSK group in the long term (57.2% vs.
1.8%, p  0.018, adjusted). LV volumes were significantly
maller and MBG and cTFC were significantly better in the
Baseline Demographic, Clinical, and AngiographTable 1 Baseline Demographic, Clinical, and
Characteristics IC
Main characteristics
Age, mean (yrs)
Male sex
Smoking
Diabetes mellitus
Hypertension
Dyslipidemia
History of pre-infarction angina
AMI localization
Anterior
Nonanterior
Peak troponin concentration
cTnT, n (ng/dl)
cTnI, n (ng/dl)
Initial ST-segment elevation, mean (mm)
Concomitant medications during PCI and in the CCU
Aspirin
Beta-blocker
LMWH
GP IIb/IIIa inhibitor
Clopidogrel
Statins
Intravenous nitroglycerin
ACE inhibitor
Angiographic characteristics
Infarct-related coronary artery
LAD
RCA
Cx
Number of diseased vessels
1
2
3
Area at risk
Baseline TIMI flow grade 0/1 (%) 1
Time from first pain to balloon dilation (min) 2
Procedural results
Slow/no-reflow
Side branch embolization
Maximum inflation pressure (atm)
No. of stents
Mean residual stenosis (%)
TIMI flow grades
0 or 1
2
3
Procedural complications
Values are mean SD or n (%) unless otherwise specified.
ACE  angiotensin-converting enzyme; AMI  anterior myocardial i
troponin T; Cx circumflex coronary artery; GP glycoprotein; ICSK
LMWH low molecular weight heparin; PCI percutaneous coronary
Infarction.CSK group in the long term as well (Tables 2 and 3, Fig. 2). fajor adverse cardiac events at follow-up. One patient in
he ICSK and 2 in the control group underwent surgical
evascularization, and 1 patient in the ICSK group had
einfarction at 1 month. Three cardiac deaths in the control
roup and 2 in the ICSK group occurred during the
aracteristicsiographic Characteristics
roup (n  51) Control Group (n  44) p Value
8.9 57.8 11.3 0.013
) 38 (84) 0.956
) 27 (61) 0.117
10 (23) 0.049
) 16 (36) 0.760
) 20 (45) 0.319
) 14 (32) 0.459
) 28 (64) 0.411
) 16 (36)
 6.5) 20 (10.5 7.4) 0.559
1.3 106.2) 24 (125.5 113.1) 0.434
10.6 14.7 8.6 0.749
0) 44 (100) 1
) 38 (86) 0.73
0) 44 (100) 1
0) 44 (100) 1
0) 44 (100) 1
) 41 (93) 1
) 21 (48) 0.21
) 37 (84) 0.75
) 28 (63) 0.51
) 8 (18)
8 (18)
) 24 (54) 0.2
) 14 (32)
6 (14)
.7 9.4) 44 (35.7 10.7) 0.145
100 1
170.2 177.5 82.8 0.01
) 5 (11) 1
2 (5) 0.68
3.0 12.8 2.8 0.68
 0.45 1.11 0.39 0.34
2.8 2.5 3.4 0.94
0 0.81
5
39
0 —
n; CCU  cardiac care unit; cTnI  cardiac troponin I; cTnT  cardiac
ronary streptokinase; LAD left anterior descending coronary artery;
ntion; RCA right coronary artery; TIMI Thrombolysis In Myocardialic ChAng
SK G
52.5
45 (88
38 (74
4 (8)
17 (33
18 (35
20 (39
28 (55
23 (45
21 (9.1
30 (10
15.3
51 (10
47 (92
51 (10
51 (10
51 (10
49 (96
32 (71
46 (90
28 (55
19 (35
5 (5)
34 (67
13 (25
4 (8)
51 (32
00
49.2
5 (10
4 (8)
13.1
1.20
2.5
0
5
46
0
nfarctio
intracoollow-up period.
Comparison of the Invasive and Noninvasive Measures of Microvascular PerfusionTable 2 Comparison of the Invasive and Noninvasive easures of Microvascular Perfusion
Univariate Multivariate LAD Subgroup
Measure ICSK Group Control Group Mean Difference (95% CI) p Value ICSK Group Control Group p Value ICSK (n  27) Control (n  24) p Value
IMR at second day (U) (48) 19.9 7.6 (37) 33.5 13.3 13.5 (18.4 to 8.6) 0.001 20.2 (14.3 to 26.2) 34.2 (27.9 to 40.4) 0.001 18.2 6.4 (24) 33.7 11.1 0.001
CFR at second day (48) 2.7 1.0 (37) 1.7 0.7 1.0 (0.6 to 1.3) 0.001 2.5 (2.1 to 3.0) 1.7 (1.3 to 2.1) 0.001 2.4 0.9 1.6 0.5 0.001
cTFC, mean
IA primary PCI (50) 29.9 9.2 (39) 31.2 8.7 1.3 (5.1 to 2.6) 0.516 32.4 (27.8 to 37.0) 32.4 (27.5 to 37.3) 0.997 31.7 10.4 33.7 8.8 0.451
At second day (49) 20.7 5.7 (33) 29.2 7.8 8.5 (11.6 to5.3) 0.001 20.7 (17.1 to 24.3) 29.2 (25.3 to 33.1) 0.001 21.4 7.0 31.0 7.4 0.001
At sixth month (37) 19.4 6.2 (30) 27.9 8.5 8.5 (12.14.9) 0.001 21.5 (16.7 26.3) 27.8 (22.6 33.0) 0.001 20.7 7.0 30.2 9.7 0.001
Myocardial blush grade
Immediately after
primary PCI
0/1 30 (60%) 32 (82%) — 0.036 — — 0.469 18 (10%) 21 (84%) 0.129
2/3 20 (40%) 7 (18%) — — — 46.2% 4 (16%)
At second day
0/1 7 (14%) 21 (64%) — 0.001 — — 0.001 6 (22%) 15 (68%) 0.002
2/3 42 (86%) 12 (36%) — 21 (78%) 7 (32%)
At sixth month
0/1 1 (3%) 10 (33%) — 0.001 — — 0.001 1 (5%) 11 (61%) 0.001
2/3 36 (97%) 20 (67%) — — — 21 (95%) 7 (39%)
DDT in the LAD (ms) at
second day
(23) 811 270 (21) 489 358 322 (130 to 514) 0.002 732 (429 to 1,035) 399 (91 to 706) 0.002 (23) 811 270 (21) 489 358 0.002
STR 90 min after
primary PCI
(47) 70.0 29.4 (37) 61.2 23.2 8.8 (3.0 to 20.5) 0.141 81.3 (65.7 to 96.9) 74.9 (59.0 to 90.8) 0.283 58.3 30.7 54.5 21.6 0.613
Values are (n) mean SD, mean (95% CI), n (%), or mean  SD.
CI  confidence interval; CFR  coronary flow reserve; cTFC  corrected Thrombolysis In Myocardial Infarction frame count; DDT  diastolic deceleration time; IA  immediately after; IMR  index of microvascular resistance; STR  ST-segment resolution in
electrocardiograms; other abbreviations as in Table 1.
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tudies aiming to understand and prevent myocardial dam-
ge developing after reperfusion are mostly targeted to
eperfusion injury and atherothrombotic embolization
ownstream of the microvasculature.
Reperfusion injury is described as a myocardial hazard
aused by oxygen free radicals, altered calcium handling,
icrovascular endothelial dysfunction, and platelet, neu-
rophil, and complement activation (5). Despite various
herapeutic interventions addressed to overcome reperfu-
ion injury (6,7), no remarkable progress could be
chieved by then. Furthermore, demonstrating the ben-
ficial effect of supersaturated oxygen infusion to the
nfarcted region in patients with anterior infarction made
he oxygen toxicity concept quite questionable (8).
Figure 2 Comparison of Infarct Size, LV End-Diastolic and -Syst
Differences between the intracoronary streptokinase (ICSK) and control groups wit
left ventricular.
eft Ventricular Volumes and Ejection Fraction at 2 Days and 6 MoTable 3 Left Ventricular Volumes and Ejection Fraction at 2 Da
Univariate Analysis
Measure ICSK Group Control Group Mean
End-systolic volume (ml)
2 days after primary
PCI
(51) 53.2 15.0 (43) 63.6 26.6 10.4 (
6 months after
primary PCI
(48) 47.3 20.2 (37) 67.2 36.6 19.9 (
End-diastolic volume (ml)
2 days after primary
PCI
(51) 110.4 23.2 (43) 116.8 33.7 6.5 (
6 months after
primary PCI
(48) 104.8 30.3 (37) 125.1 48.7 20.3 (
Left ventricular ejection
fraction (%)
2 days after primary
PCI
(51) 51.7 8.6 (43) 47.1 9.9 4.7 (
6 months after
primary PCI
(48) 55.5 9.5 (37) 48.5 11.4 7.0 (2
Infarct size at 6
months (%)
(45) 18.3 13.3 (35) 28.8 15.6 10.5 (
alues are (n) mean  SD or mean (95% CI). Left ventricular volumes were determined with the
Abbreviations as in Tables 1 and 2.Atherothrombotic embolization might be the explanation
or ongoing myocardial damage after reperfusion. But dis-
repant results of the distal protection studies suggested that
istal embolization does not look like a determining mech-
nism alone (9,10).
There are several reports suggesting that another
echanism may play a role in microvascular malperfu-
ion. It has been demonstrated in ischemia/reperfusion
odels that de novo fibrin depositions occur in the
icrovasculature of the brain (11), small intestine (12),
nd kidney (13). This autochthonous fibrin mass binds
o endothelial junctional adhesion molecules (VE-
adherin), constitutes a mesh, and tends to persist in the
icrovasculature (14). On the other hand, although
liminating epicardial occlusion re-establishes perfusion,
olumes, and Infarct Size Between the Groups
ect to scintigraphic and echocardiographic findings at long-term follow-up. LV 
and Infarct Size at 6 Monthsd 6 Months and Infarct Size at 6 Months
Multivariate Analysis
ence p Value ICSK Group Control Group p Value
o1.2) 0.027 47.1 (37.2 to 57.2) 58.0 (47.4 to 68.7) 0.077
o6.5) 0.004 41.1 (26.4 to 55.8) 60.9 (45.1 to 76.8) 0.009
o 5.6) 0.291 101.1 (86.9 to 115.3) 110.9 (95.9 to 125.9) 0.101
o2.0) 0.031 95.5 (74.5 to 116.5) 118.3 (95.6 to 141.0) 0.006
8.5) 0.016 53.5 (49.0 to 58.1) 50.3 (45.5 to 55.1) 0.097
5.5) 0.003 57.2 (51.4 to 63.0) 51.8 (47.6 to 58.1) 0.018
o4.1) 0.002 22.7 (15.0 to 30.4) 32.9 (24.9 to 41.0) 0.003
chocardiography. Infarct size was determined by single-photon emission computed tomography.olic V
h respnthsys an
Differ
19.5 t
33.3 t
18.6 t
38.5 t
0.9 to
.5 to 1
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ater get entrapped in the microvasculature that contains
he fibrin mesh. Blood cells create obstructive plugs and
ause significant congestion by enmeshing passively or
inding to fibrin actively with their receptors (15). In this
low-flow condition, fibrinogen also contributes to im-
eding flow via facilitating blood cell aggregation and
ediating the inflammatory process (16,17).
In light of the above-mentioned facts, reperfusion injury
ight be considered as the consequence of insufficient
erfusion instead of the injury of reperfusion itself. There-
ore, removing fibrin and fibrinogen deposition from the
icrovasculature can be a suitable target for achieving better
yocardial perfusion.
In our pilot study, it had been demonstrated that ICSK
dministration immediately after primary PCI significantly
mproves microvascular perfusion. Nevertheless, the sample
ize of the study was not enough to evaluate the effect of this
ode of therapy on long-term infarct size, ventricular
olumes, and LV function.
In the current study, it has been shown that adjunctive
CSK therapy prevents LV dilation, preserves systolic
unction, and decreases long-term LV infarct size by 31%
ompared with conventional primary PCI. The absolute
ifference in infarct size was 10% between the groups. No
ther study on adjunctive therapy to primary PCI has
eported this amount of benefit. Because the relation
etween infarct size and mortality is well known, a 31%
elative reduction of infarct size promises a substantial
rognostic benefit. Furthermore, significantly smaller LV
olumes and higher ejection fractions were observed in
he ICSK group in the long-term follow-up.
tudy limitations. This is a relatively small, single-center
tudy. Although the procedural recordings and all
ollow-up parameters were analyzed by blinded investi-
ators, the study drug was administered in an open-label
ashion. Finally, none of the methods using for evaluating
he efficacy of adjunctive therapies to primary PCI is
recise. Inherent limitations of the methods used in this
tudy have to be taken into consideration in the inter-
retation of the results.
onclusions
ow-dose ICSK administered immediately after primary
CI improves microvascular perfusion, decreases long-term
nfarct size, and improves LV volumes and function. These
ositive effects on main determinants promise parallel
hanges in long-term clinical outcomes.
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